Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The promise of personalized medicine to deliver "the right treatments at the right time to the right person" is the next frontier in healthcare. However, to implement personalized medicine in chronic diseases such as diabetes mellitus and diabetic kidney disease (DKD), a number of different aspects need to be taken into account. Better risk stratification and more precise options for treatment need to be developed and included in clinical practice guidelines. A patient's unique psychological, social and environmental situation also drive disease progression and outcomes. Appraising the cost effectiveness of precision medicines is necessary, not just as the cost of new therapies, but also the cost of diagnosis with novel methodologies and averted complications. As the prevalence of DKD grows worldwide to epidemic proportions, challenges such as global disparities in resources, access to healthcare and prevalence need to be addressed. This review considers these issues to achieve the short and longer-term goals of implementing personalized medicine in clinical practice.

Original publication

DOI

10.1111/dom.13412

Type

Journal article

Journal

Diabetes, obesity & metabolism

Publication Date

10/2018

Volume

20 Suppl 3

Pages

24 - 29

Addresses

Department of Internal Medicine, Antonius Ziekenhuis, Sneek, the Netherlands.

Keywords

Humans, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Attitude to Health, Systems Biology, Professional Practice, Practice Guidelines as Topic, Global Health, Precision Medicine